Nature Reviews Clinical Oncology - Table of Contents alert Volume 10 Issue 3

TABLE OF CONTENTS
March 2013 Volume 10 Number 3
Impact Factor 9.113 *	In this issue Research Highlights News and Views Reviews Perspectives Also this month  Featured article: Colorectal cancer screening—optimizing current strategies and new directions Ernst J. Kuipers, Thomas Rösch & Michael Bretthauer
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Molecular Dx: Cancer Drug Development www.moleculardiagnostics-cancer.com 18 - 20 June 2013 | Boston, MA Discover the next generation of MDx, perfect biomarker development and ensure clinical success www.moleculardiagnostics-cancer.com
Advertisement
New Nature Journals iPad app Read Nature anytime, anywhere. Subscribe to Nature on the iPad for only $35.99* Download the new app from the app store. *Apple exchange rates apply to international prices.
RESEARCH HIGHLIGHTS Top Breast cancer: ALTTO: wake-up call for setting up clinical trials Published online: 12 February 2013 p121 | doi:10.1038/nrclinonc.2013.20 PDF Haematological cancer: First randomized study Published online: 05 February 2013 p122 | doi:10.1038/nrclinonc.2013.15 PDF Skin cancer: Novel mouse model reveals strategy to delay drug resistance in melanoma Published online: 22 January 2013 p123 | doi:10.1038/nrclinonc.2013.11 PDF Urological cancer: Life after prostate cancer treatment Published online: 12 February 2013 p123 | doi:10.1038/nrclinonc.2013.21 PDF Urological cancer: More options for prostate cancer Published online: 22 January 2013 p123 | doi:10.1038/nrclinonc.2013.6 PDF Imaging: Radioactive microspheres—see and destroy Published online: 29 January 2013 p124 | doi:10.1038/nrclinonc.2013.13 PDF Breast cancer: Circulating tumour cells help to guide treatment Published online: 05 February 2013 p124 | doi:10.1038/nrclinonc.2013.18 PDF IN BRIEF Radiotherapy: MRI underestimates the size of pancreatic adenocarcinoma | Haematological cancer: No survival improvement with thalidomide and prednisone | Genetics: NF1 drives resistance to RAF inhibition in melanoma PDF Clinical Oncology JOBS of the week Post-Doctoral Fellowships in Basic and Translational Neuro-Oncology The Feinstein Institute for Medical Research Faculty, Research Fellows / Postdoctoral Fellows Positions Available Tsinghua University School of Medicine 16 open positions with Marie Curie mobility fellowships European School of Molecular Medicine (SEMM) Post Doctoral Fellow Genome Institute of Singapore More Science jobs from Clinical Oncology EVENT The International Congress on Oncological Perspectives of Fertility Preservation: Gynecological & Breast Cancer (OP/FP) 21.-23.03.13 Berlin, Germany More science events from
NEWS AND VIEWS		Top
Breast cancer: Tamoxifen—when more might be better Carlos Caldas & Ian F. Tannock Published online: 05 February 2013 p125 | doi:10.1038/nrclinonc.2013.17 The ATLAS trial demonstrated improved survival for women with oestrogen receptor-positive breast cancer who continued taking tamoxifen for 10 years compared to stopping at 5 years. Women for whom absolute benefit outweighs adverse-effects should be selected based on their risk of recurrence beyond 5 years; support must be provided to maintain compliance. Full Text | PDF
Prostate cancer: The androgen receptor remains front and centre Philip J. Saylor Published online: 05 February 2013 p126 | doi:10.1038/nrclinonc.2013.14 Abiraterone is an androgen biosynthesis inhibitor that further lowers testosterone in men receiving standard androgen deprivation therapy for metastatic castration-resistant prostate cancer. Previously shown to improve survival in patients after treatment with docetaxel, abiraterone has demonstrated benefits in a new phase III trial in men who are chemotherapy naive. Full Text | PDF
Breast cancer: Investment biobanking—increased returns from tissue samples Valerie Speirs & Adrienne Morgan Published online: 05 February 2013 p128 | doi:10.1038/nrclinonc.2013.19 Researchers now expect that samples obtained from biobanks are accompanied with well-annotated clinical data. Opened in 2010, the Breast Cancer Campaign Tissue Bank takes this criterion a step further: researchers obtaining tissues are required to return the data they generate from every sample back to the Tissue Bank. Full Text | PDF
REVIEWS		Top
Colorectal cancer screening—optimizing current strategies and new directions Ernst J. Kuipers, Thomas Rösch & Michael Bretthauer Published online: 05 February 2013 p130 | doi:10.1038/nrclinonc.2013.12 Many methods are available for colorectal cancer (CRC) screening, ranging from noninvasive stool tests to endoscopy. In this Review, E. J. Kuipers et al. argue that the strength of any single test must be viewed in the context of a range of factors across the screening programme, including test characteristics, uptake, screenee autonomy, cost, endoscopy performance and long-term follow-up. Abstract | Full Text | PDF
Development of PI3K inhibitors: lessons learned from early clinical trials Jordi Rodon, Rodrigo Dienstmann, Violeta Serra & Josep Tabernero Published online: 12 February 2013 p143 | doi:10.1038/nrclinonc.2013.10 Agents targeting the PI3K/AKT/mTOR pathway have been shown to be safe and effective in treating a number of tumour types. This Review outlines the background to these inhibitors and discusses the second-generation inhibitors of this pathway. The authors propose that the way forward for the development of inhibitors of the PI3K/AKT/mTOR pathway might be a systems biology approach and biomarker-driven studies. Abstract | Full Text | PDF | Supplementary information
Safety and feasibility of targeted agent combinations in solid tumours Sook Ryun Park, Myrtle Davis, James H. Doroshow & Shivaani Kummar Published online: 29 January 2013 p154 | doi:10.1038/nrclinonc.2012.245 Combination strategies of molecular-targeted agents (MTAs) are being used in the hope of optimizing antitumour efficacy and to minimize the development of resistance, but very little effort is focused on molecular vulnerabilities of normal tissues. This Review discusses the main toxicities and the lack of tolerability of some common MTA combinations, and highlights what steps can be introduced for new preclinical testing paradigms for the assessment of chronic toxicities. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION Translating metastasis-related biomarkers to the clinic—progress and pitfalls François-Clément Bidard, Jean-Yves Pierga, Jean-Charles Soria & Jean Paul Thiery Published online: 05 February 2013 p169 | doi:10.1038/nrclinonc.2013.4 The majority of patients with cancer do not die as a result of the primary tumour, rather from the metastases that arise from that tumour. The mechanisms and markers of metastasis have, therefore, been a main focus of both clinical and preclinical research. This Perspectives article discusses the hurdles that need to be overcome to successfully translate the preclinical metastasis research into the clinic. Abstract | Full Text | PDF
Advertisement
Visit the Nature Reviews Clinical Oncology website: - Advanced online publication - Search across related content from nature.com - Web feeds (RSS) - Downloadable PowerPoint slides of figures and supplementary information - Links to the European School of Oncology, including e-grandrounds
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2011. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.